The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations

NCT ID: NCT07035652

Last Updated: 2025-06-25

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 81 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-15
• Study Completion Date: 2026-11-13

Brief Summary

The objectives of the proposed study are to investigate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and prliminary efficacy of XH-S004 in moderate to severe COPD patients with a stale standards of care (SOC).

Detailed Description

This study is a multicenter, double-blind, placebo-controlled, up-titration study conducted in china, aimed at evaluating the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of XH-S004 administered once daily for 140 days in COPD patients.

This study plans to enroll 81 COPD patients. Patients who sign the informed consent form will be screened according to the enrollment criteria, and randomly divided into 2 groups in 2:1 ratio (XH-S004 group: 54 participants and placebo group: 27 participants). Participants in XH-S004 group will receive XH-S004 20 mg for 28 days in treatment period 1, then up-titrated to XH-S004 40 mg for 84 days in treatment period 2, finally continue with XH-S004 60 mg for 28 days in treamtment period 3. Participants in placebo group will receive matching placebo from day 1 to day 140 (140 days in total).

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Arm1: Participant Group

Up-titration design: prticipants received XH-S004 20 mg once daily (QD) from day 1 to day 28 in treatment period 1, XH-S004 40 mg once daily (QD) from day 29 to day 112 in treatment period 2, and XH-S004 60 mg once daily (QD) from day 113 to day 140 in treatment period 3.

Pharmaceutical form: Tablets Route of administration: Oral

Group Type: EXPERIMENTAL

XH-S004 20 mg, 40 mg or 60 mg

Intervention Type: OTHER

Administered once per day for 140 days.

Participant Group

Participants received the matching placebo once daily (QD) from day 1 to day 140 in treatment period 1, treatment period 2 and treatment period 3.

Pharmaceutical form: Tablets Route of administration: Oral

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Administered once per day for 140 days.

Interventions

XH-S004 20 mg, 40 mg or 60 mg

Administered once per day for 140 days.

Intervention Type: OTHER

Placebo

Administered once per day for 140 days.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Sign the informed consent form (ICF);

2. Male or Female participants ages 40-80 (inclusive);

3. BMI ≥ 18.5 kg/m2 and ≤ 26 kg/m2, with male weight ≥50 kg and female weight ≥45 kg (inclusive);

4. Patients diagnosed with COPD according to 2024 GOLD consensus had a medical record or relevant documentation proving a history of COPD for ≥12 months at screening visit;

5. Current or former smokers with a smoking history of ≥10 pack-years;

6. Post-bronchodilator FEV1/ forced vital capacity [FVC] ratio <0.70 and post-bronchodilator FEV1 % predicted >30% and ≤70%.

7. Sputum volume≥10ml/day at screening visit;

8. with a documented history: 1) Moderate-to-severe COPD patients with a stable SOC therapy prior to signing ICF, including LABA, LAMA, LABA/LAMA, LABA/LAMA/ICS (evaluated by investigator to confirm the treatment regimen complies with clinical practice); Continuous use with a stable dosage for ≥1 month prior to randomization; Medication compliance between 80% and 120% from signing ICF to randomization; 2) Acute exacerbation history of ≥2 moderate or ≥1 severe requiring hospitalization within 12 months prior to screening.

9. Medical Research Council (MRC) Dyspnea Scale grade ≥2.

10. COPD Assessment Test (CAT)≥10

Exclusion Criteria

1. Have a primary diagnosis of asthma as determined by the investigator;

2. During screening period, WBC<the lower limit of normal range, or absolute neutrophil count<the lower limit of normal range;

3. During screening period, blood eosinophils ≥300 cells/microliter;

4. Pregnant and lactating females

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

S-INFINITY Pharmaceuticals Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Bin Cao

Role: CONTACT

caobin_ben@163.com

+86 13911318339

Yeming Wang

Role: CONTACT

wwyymm_love@163.c0m

+86 18810663558

Facility Contacts

Bin Cao

Role: primary

caobin_ben@163.com

+86 13911318339

Other Identifiers

XH-S004-102

Identifier Type: -

Identifier Source: org_study_id